If you want your cath lab to run efficiently and safely, you need a director with clear vision and the ability to take charge, even—make that especially— in times of strife, a physician leader said Sept. 13 at the Transcatheter Cardiovascular Therapeutics scientific session.

Google Glass one day could become an interventional cardiologist’s new best friend, based on a demonstration Sept. 15 at the Transcatheter Cardiovascular Therapeutics scientific session that showed how the technology was used during a transradial PCI.

Germany's ground-breaking use of CT scanners in ambulances to assess for possible stroke inspired one program in Houston to follow suit. Supporters predict it will transform care in the future. 

Using 3D imaging and computer models to allow fast computation, researchers developed a method they propose may be safer, more efficient and cost less than traditional wire-based fractional flow reserve (FFR) calculations for assessing coronary stenosis.

Cardiologists at the Cleveland Clinic reduced radiation doses by 22 percent for diagnostic catheterizations and by 32 percent for PCI by leveraging new imaging technology, according to results published online Aug. 5 in Circulation: Cardiovascular Interventions. 

Boston Scientific Corporation has initiated full commercial launch of the new POLARIS Imaging System.  This system will support the Boston Scientific family of intravascular ultrasound (IVUS) catheters, including coronary, peripheral and intra-cardiac echo products.  The POLARIS System offers enhanced ease-of-use and more powerful processing capabilities.  Its modular design would also support the planned release of new Boston Scientific imaging products including a fractional flow reserve (FFR) wire, a new family of IVUS catheters, enhanced software features and better system control tools.

Moving toward U.S. market introduction of its novel medical device to treat peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced that it recently submitted the final module of its pre-market approval (PMA) application for the IN.PACT Admiral drug-coated balloon to the U.S. Food and Drug Administration (FDA). The application includes data that demonstrates superior clinical outcomes compared with conventional angioplasty, with the lowest rates of repeat procedures (target lesion revascularization) and the highest rate of uninterrupted blood flow (primary patency) at 12 months ever reported for the interventional treatment of peripheral artery disease.

The Accreditation for Cardiovascular Excellence (ACE) is proud to announce the participation of every ACE Board Member at the 2014 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions in Las Vegas, NV, May 28-31, 2014. First, Charles E. Chambers, MD, FSCAI, President-Elect of SCAI and ACE Board Member, will kick-off SCAI's inaugural Cath Lab Leadership Boot Camp, a unique two-day educational event designed to address the needs of cath lab managers and directors and those who aspire to those roles.